Literature DB >> 8872901

Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide.

W J Karpus1, K J Kennedy, W S Smith, S D Miller.   

Abstract

Peripheral antigen-specific tolerance can be induced by feeding protein antigens. The mechanism has been described as either clonal anergy/deletion or induction of antigen-specific regulatory cells that produce transforming growth factor-beta (TGF-beta). These two mechanisms have been linked to the magnitude and frequency of the dose of antigen fed; a single high dose induces anergy/deletion, whereas multiple low doses of antigen induce TGF-beta-secreting regulatory cells. In the present study, we investigated the mechanisms of feeding soluble peptides of proteolipid protein (PLP) for prevention of experimental autoimmune encephalomyelitis (EAE) induced by either intact PLP or the immunodominant PLP139-151 peptide. Feeding PLP139-151 prevented acute and relapsing EAE induced by either PLP139-151 or intact PLP. PLP139-151 feeding induced anergy in the T helper 1 (Th1) population as measured by an inhibition of both proliferation and interferon-gamma (IFN-gamma) production. Interleukin-4 (IL-4) production was increased, but increased TGF-beta production was not observed. Importantly, PLP139-151 feeding induced anergy in peripheral and central nervous system (CNS)-in-filtrating T cells. Feeding of the subdominant PLP epitope (PLP178-191) failed to inhibit EAE induced by PLP139-151; therefore, oral tolerance was not due to induction of bystander suppression. These results demonstrate that both acute and relapsing paralysis in EAE can be prevented by feeding the immunodominant peptide of PLP.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8872901     DOI: 10.1002/(SICI)1097-4547(19960815)45:4<410::AID-JNR10>3.0.CO;2-4

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  14 in total

Review 1.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

2.  Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial.

Authors:  Eran Israeli; Eran Goldin; Oren Shibolet; Athalia Klein; Nilla Hemed; Dean Engelhardt; Elazar Rabbani; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

3.  Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.

Authors:  Liliana R Pires; Fernanda Marques; João Carlos Sousa; João Cerqueira; Inês Mendes Pinto
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

Review 4.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

5.  ILDR2-Fc Is a Novel Regulator of Immune Homeostasis and Inducer of Antigen-Specific Immune Tolerance.

Authors:  Joseph R Podojil; Iris Hecht; Ming-Yi Chiang; Ilan Vaknin; Inbal Barbiro; Amit Novik; Eyal Neria; Galit Rotman; Stephen D Miller
Journal:  J Immunol       Date:  2018-02-05       Impact factor: 5.422

6.  Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.

Authors:  P I Karachunski; N S Ostlie; D K Okita; B M Conti-Fine
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 7.  Tolerogenic antigen-presenting cells: regulation of the immune response by TGF-beta-treated antigen-presenting cells.

Authors:  Michele M Kosiewicz; Pascale Alard
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

8.  Mice deficient for CCR6 fail to control chronic experimental autoimmune encephalomyelitis.

Authors:  Adam Elhofy; R William Depaolo; Sergio A Lira; Nicholas W Lukacs; William J Karpus
Journal:  J Neuroimmunol       Date:  2009-06-17       Impact factor: 3.478

Review 9.  Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis.

Authors:  Danielle M Turley; Stephen D Miller
Journal:  Results Probl Cell Differ       Date:  2010

Review 10.  Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.

Authors:  Jeffrey A Bluestone; Hélène Bour-Jordan
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-11-01       Impact factor: 10.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.